Directed evolution of metalloproteinase inhibitor TIMP-1 for selective inhibition of MMP-9 exploits catalytic and fibronectin domain interactions
Journal of Biological Chemistry · 2025-06 · 301 (6) · 110258
DOI: 10.1016/j.jbc.2025.110258 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Biological Chemistry, 2025-06. Verfasst von Alireza Shoari und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cancer Biology, Mayo Clinic, Jacksonville, Florida, USA. Hauptthemen laut MEDLINE: Tissue Inhibitor of Metalloproteinase-1, Matrix Metalloproteinase 9, Fibronectins, Matrix Metalloproteinase Inhibitors. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS, NIGMS NIH HHS, NHLBI NIH HHS.
Abstract (Originalsprache)
Matrix metalloproteinase-9 (MMP-9) is a critical enzyme involved in extracellular matrix degradation and is strongly implicated in many diseases, including triple-negative breast cancer and other poor prognosis cancers. Selective inhibition of MMP-9 is therefore a promising therapeutic strategy. However, development of MMP inhibitors has been hindered by challenges in achieving specificity, with past efforts failing in clinical trials due to off-target effects and associated toxicity. Here, we present a novel approach to overcoming these challenges by engineering tissue inhibitor of metalloproteinases-1 (TIMP-1), a natural broad-spectrum MMP inhibitor, to achieve enhanced specificity and affinity for MMP-9. We demonstrate that TIMP-1 can be strategically engineered to selectively inhibit MMP-9 through modulating interactions not only with the catalytic domain but also with the unique fibronectin (FN) domains. By leveraging yeast surface display with strategic library design, we identified TIMP-1 variants that exploit multiple surface epitopes to optimize interactions with both the catalytic and FN domains of MMP-9. Molecular dynamics simulations further suggest how modifications in the N-terminal and C-terminal domains of TIMP-1 drive these selective interactions. The top engineered TIMP-1 variant exhibited significantly improved selectivity for MMP-9 in a manner dependent upon novel interactions with the FN domains, as validated through inhibition kinetics. This variant also demonstrated potent inhibition of MMP-9-driven triple-negative breast cancer cell invasiveness, underscoring the therapeutic potential of this approach. Our study highlights the versatility of TIMP-1 as a scaffold that can be optimized for highly selective MMP inhibition, providing new avenues for the development of targeted therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cancer Biology, Mayo Clinic, Jacksonville, Florida, USA.
- Chemical and Biological Engineering Department, Tufts University, Medford, Massachusetts, USA.
- Chemical and Materials Engineering, University of Nevada, Reno, Nevada, USA.
- Department of Cancer Biology, Mayo Clinic, Jacksonville, Florida, USA. Electronic address: radisky.evette@mayo.edu.
Förderung
- NCI NIH HHS
- NIGMS NIH HHS
- NHLBI NIH HHS
- National Heart Lung and Blood Institute
- National Institutes of Health National Cancer Institute
- Mayo Clinic
- National Institutes of Health
- United Nations Foundation
Zitieren
APA
Shoari, A., Coban, M. A., Hockla, A., Rezhdo, A., Dimesa, A. M., Raeeszadeh-Sarmazdeh, M., Van Deventer, J. A., & Radisky, E. S. (2025). Directed evolution of metalloproteinase inhibitor TIMP-1 for selective inhibition of MMP-9 exploits catalytic and fibronectin domain interactions. Journal of Biological Chemistry, 301(6), 110258. https://doi.org/10.1016/j.jbc.2025.110258
Vancouver
Shoari A, Coban MA, Hockla A, Rezhdo A, Dimesa AM, Raeeszadeh-Sarmazdeh M, et al. Directed evolution of metalloproteinase inhibitor TIMP-1 for selective inhibition of MMP-9 exploits catalytic and fibronectin domain interactions. Journal of Biological Chemistry. 2025;301(6):110258. doi:10.1016/j.jbc.2025.110258
BibTeX
@article{Shoari2025,
author = {Shoari, Alireza and Coban, Mathew A and Hockla, Alexandra and Rezhdo, Arlinda and Dimesa, Alexandra M and Raeeszadeh-Sarmazdeh, Maryam and Van Deventer, James A and Radisky, Evette S},
title = {Directed evolution of metalloproteinase inhibitor TIMP-1 for selective inhibition of MMP-9 exploits catalytic and fibronectin domain interactions},
journal = {Journal of Biological Chemistry},
year = {2025},
volume = {301},
number = {6},
pages = {110258},
doi = {10.1016/j.jbc.2025.110258}
}
EUVIMED